Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I / II open‐label, dose escalation study

Author:

Cousin Sophie1ORCID,Blay Jean‐Yves2ORCID,Garcia Irene Braña3,Bono Johann S.4,Le Tourneau Christophe5,Moreno Victor6,Trigo Jose7,Hann Christine L.8,Azad Arun A.9,Im Seock‐Ah10ORCID,Cassier Philippe A.2,French Christopher A.11,Italiano Antoine12ORCID,Keedy Vicki L.13,Plummer Ruth14,Sablin Marie‐Paule5,Hemming Matthew L.15,Ferron‐Brady Geraldine16,Wyce Anastasia16,Khaled Ahmed16,Datta Antara16,Foley Shawn W.16,McCabe Michael T.16,Wu Yuehui16,Horner Thierry16,Kremer Brandon E.16,Dhar Arindam16,O'Dwyer Peter J.17,Shapiro Geoffrey I.15ORCID,Piha‐Paul Sarina A.18ORCID

Affiliation:

1. Medical Oncology Department Institut Bergonié Bordeaux France

2. Medical Oncology Department Centre Léon Bérard Lyon France

3. Medical Oncology Department Vall d'Hebron University Hospital, Vall d'Hebron Institut of Oncology (VHIO) Barcelona Spain

4. The Institute of Cancer Research and Royal Marsden Hospital London UK

5. Department of Drug Development and Innovation (D3i), INSERM U900 Research Unit Institut Curie, Paris‐Saclay University Paris and Saint‐Cloud France

6. Medical Oncology, START Madrid‐FJD Fundación Jiménez Díaz Hospital Madrid Spain

7. Medical Oncology Department Hospital Universitario Virgen de la Victoria y Regional, IBIMA Málaga Spain

8. Johns Hopkins University School of Medicine Baltimore Maryland USA

9. Peter MacCallum Cancer Centre Victoria Australia

10. Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine Seoul Republic of Korea

11. Department of Pathology Brigham and Women's Hospital Boston Massachusetts USA

12. Early Phase Trials and Sarcoma Units Institut Bergonié Bordeaux France

13. Department of Medicine, Hematology and Oncology Vanderbilt‐Ingram Cancer Center Nashville Tennessee USA

14. Translational and Clinical Research Institute Newcastle University Newcastle upon Tyne UK

15. Department of Medical Oncology, Dana‐Farber Cancer Institute and Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts USA

16. GSK Collegeville Pennsylvania USA

17. Abramson Cancer Center University of Pennsylvania Philadelphia Pennsylvania USA

18. Department of Investigational Cancer Therapeutics University of Texas MD Anderson Cancer Center Houston Texas USA

Funder

GlaxoSmithKline

Publisher

Wiley

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3